Compare RNGR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | CCCC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.2M | 404.7M |
| IPO Year | 2017 | 2020 |
| Metric | RNGR | CCCC |
|---|---|---|
| Price | $15.42 | $4.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $12.20 |
| AVG Volume (30 Days) | 174.7K | ★ 3.4M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $23.86 | N/A |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $128.50 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $11.14 | $1.44 |
| 52 Week High | $18.82 | $5.17 |
| Indicator | RNGR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 57.67 |
| Support Level | $14.90 | $2.10 |
| Resistance Level | $16.71 | $4.60 |
| Average True Range (ATR) | 0.50 | 0.38 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 44.41 | 44.41 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.